ES2178093T5
(es)
|
1995-11-17 |
2009-02-16 |
Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) |
Derivados de epotilon y su preparacion.
|
PT941227E
(pt)
*
|
1996-11-18 |
2004-08-31 |
Biotechnolog Forschung Mbh Gbf |
Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
|
US6867305B2
(en)
*
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
JP4579351B2
(ja)
|
1996-12-03 |
2010-11-10 |
スローン−ケッタリング インスティトュート フォア キャンサー リサーチ |
エポチロンの合成とその中間体及びその類似物並びにその使用
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
FR2775187B1
(fr)
*
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
US6399638B1
(en)
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
DE19820599A1
(de)
*
|
1998-05-08 |
1999-11-11 |
Biotechnolog Forschung Gmbh |
Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
NZ511722A
(en)
|
1998-11-20 |
2004-05-28 |
Kosan Biosciences Inc |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
US6262094B1
(en)
*
|
1999-02-22 |
2001-07-17 |
Bristol-Myers Squibb Company |
C-21 modified epothilones
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
RU2260592C9
(ru)
|
1999-04-15 |
2017-04-07 |
Бристол-Маерс Сквибб Ко. |
Циклические ингибиторы протеинтирозинкиназ
|
EP1232149A2
(en)
*
|
1999-11-24 |
2002-08-21 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Fungicidal melithiazole derivatives
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
US20020045609A1
(en)
*
|
2000-05-26 |
2002-04-18 |
Gary Ashley |
Epothilone derivatives and methods for making and using the same
|
EP1319011B1
(de)
*
|
2000-09-22 |
2012-12-05 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Triazolo-epothilone
|
AU2002213248A1
(en)
*
|
2000-10-13 |
2002-04-22 |
The University Of Mississipi |
Synthesis of epothilones and relates analogs
|
NZ526871A
(en)
|
2001-01-25 |
2006-01-27 |
Bristol Myers Squibb Co |
Pharmaceutical dosage forms of epothilones for oral administration
|
JP2004521122A
(ja)
|
2001-01-25 |
2004-07-15 |
ブリストル−マイヤーズ スクイブ カンパニー |
エポチロン類似体の非経口製剤
|
HU229349B1
(en)
|
2001-01-25 |
2013-11-28 |
Bristol Myers Squibb Co |
Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
|
EE200300396A
(et)
|
2001-02-20 |
2003-12-15 |
Bristol-Myers Squibb Company |
Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
|
CA2438598A1
(en)
|
2001-02-20 |
2002-08-29 |
Francis Y. F. Lee |
Epothilone derivatives for the treatment of refractory tumors
|
NZ527557A
(en)
*
|
2001-02-27 |
2005-05-27 |
Biotechnolog Forschung Gmbh |
Degradation of epothilones and ethynyl substituted epothilones
|
CZ305799B6
(cs)
|
2001-03-14 |
2016-03-23 |
Bristol-Myers Squibb Company |
Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
|
EP1392664A4
(en)
*
|
2001-06-01 |
2005-01-26 |
Bristol Myers Squibb Co |
EPOTHILONE DERIVATIVES
|
CN100536841C
(zh)
*
|
2001-08-23 |
2009-09-09 |
诺瓦提斯公司 |
环丙基和环丁基埃坡霉素类似物
|
WO2003026744A1
(en)
*
|
2001-09-25 |
2003-04-03 |
Alcon, Inc. |
The use of epothilones and analogs in conjunction with ophthalmic surgery
|
DE60224299T2
(de)
*
|
2001-10-25 |
2008-12-11 |
Novartis Ag |
Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
|
EP1456664A1
(en)
*
|
2001-12-07 |
2004-09-15 |
Novartis AG |
Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
|
CA2471509A1
(en)
|
2002-01-14 |
2003-07-17 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
TW200303202A
(en)
*
|
2002-02-15 |
2003-09-01 |
Bristol Myers Squibb Co |
Method of preparation of 21-amino epothilone derivatives
|
DE60330651D1
(en)
*
|
2002-03-12 |
2010-02-04 |
Bristol Myers Squibb Co |
C3-cyanoepothilonderivate
|
AU2003218107A1
(en)
|
2002-03-12 |
2003-09-29 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
TW200403994A
(en)
*
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7008936B2
(en)
|
2002-06-14 |
2006-03-07 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
WO2004014919A1
(en)
*
|
2002-08-02 |
2004-02-19 |
Novartis Ag |
Epothilone derivatives
|
EP1506203B1
(en)
*
|
2002-08-23 |
2007-01-03 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7384964B2
(en)
*
|
2002-08-23 |
2008-06-10 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
KR101406635B1
(ko)
|
2002-09-23 |
2014-06-11 |
브리스톨-마이어스 스큅 컴퍼니 |
에포틸론 b의 제조, 분리 및 정제 방법, 및 에포틸론 b의 x-선 결정 구조
|
AU2003267751A1
(en)
*
|
2002-10-15 |
2004-05-04 |
Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College |
Use of epothilone derivatives for the treatment of hyperparathyroidism
|
US7632858B2
(en)
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
EP1559447A1
(en)
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
GB0405898D0
(en)
*
|
2004-03-16 |
2004-04-21 |
Novartis Ag |
Organic compounds
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
AU2006336468B2
(en)
|
2005-02-11 |
2012-04-12 |
University Of Southern California |
Method of expressing proteins with disulfide bridges
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Birドメイン結合化合物
|
US7893268B2
(en)
*
|
2005-07-27 |
2011-02-22 |
University Of Toledo |
Epithiolone analogues
|
US8003801B2
(en)
*
|
2005-11-22 |
2011-08-23 |
The Scripps Research Institute |
Chemical synthesis of a highly potent epothilone
|
US7653731B2
(en)
*
|
2006-02-24 |
2010-01-26 |
Microsoft Corporation |
Management of connections to external data
|
EP2029156A4
(en)
*
|
2006-05-01 |
2010-07-21 |
Univ Southern California |
POLY THERAPY FOR TREATING CANCER
|
WO2007131366A1
(en)
|
2006-05-16 |
2007-11-22 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
EP2089411A4
(en)
|
2006-12-04 |
2010-01-27 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA
|
WO2008098216A2
(en)
|
2007-02-08 |
2008-08-14 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to prevent cancer with cupredoxins
|
WO2008118327A1
(en)
*
|
2007-03-23 |
2008-10-02 |
University Of Toledo |
Conformationally restrained epothilone analogues as anti-leukemic agents
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
CA2729620A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Pharma Mar, S.A. |
Antitumoral macrolides
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
AU2011214057B2
(en)
|
2010-02-12 |
2016-11-17 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treating autoimmune and other diseases
|
BR112013018534B1
(pt)
|
2011-01-20 |
2021-04-06 |
Board Of Regents, The University Of Texas System |
Agente de contraste, seus métodos de preparação, e produto de combinação
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
CA2858806A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
WO2014075391A1
(zh)
|
2012-11-17 |
2014-05-22 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
US9862692B2
(en)
*
|
2013-01-23 |
2018-01-09 |
The University Of Toledo |
Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
EP3010548A1
(en)
|
2013-06-21 |
2016-04-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
MX2018004696A
(es)
*
|
2015-10-16 |
2018-11-29 |
Univ Rice William M |
Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|